TMS for Chronic Pain
Chronic Pain
Commercial/Clinical DevelopmentActive
Key Facts
About Magstim
Founded in 1992, Magstim is a pioneering private company in the neurotechnology and medical device sector, with a 30+ year history. It operates a commercial-stage business model, generating revenue from the sale of its TMS, EEG, and tDCS systems to research institutions and clinical providers globally. The company's technology is clinically validated, with its TMS systems forming the basis for FDA-cleared treatments for conditions like Major Depressive Disorder (MDD). Magstim's strategy focuses on expanding clinical indications for its neuromodulation platforms and integrating its modalities for advanced brain research and therapy.
View full company profileTherapeutic Areas
Other Chronic Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-160 | SciSparc | Preclinical |
| Injectrode Platform for Chronic Pain | Neuronoff | Pre-clinical |
| Novel PNS System | Nervonik | First-in-Human Completed |
| Pain Pipeline | Centrexion Therapeutics | Clinical Stage |
| High-Definition Spinal Cord Stimulation | Micro-Leads | Unknown |
| Precision Medicine for Pain | MindX Sciences | Commercial |
| Chronic Pain Program | Current Surgical | Research |
| N-19a | Neurocarrus | Pre-clinical |
| Nav1.7 ASO | Quiver Bioscience | Discovery |
| Nav1.8 ASO | Quiver Bioscience | Discovery |
| Dual Nav1.7/1.8 ASO | Quiver Bioscience | Discovery |
| Platform Enhancements | Nevro | R&D |